Emily Menendez

GU Oncology Now

A research team recently carried out a study to <a href="https://pubmed.ncbi.nlm.nih.gov/36457489/" target="_blank" rel="noopener">determine the effectiveness</a> of Fluorine-18 (18F)-prostate-specific membrane antigen (PSMA)-1007 positron emission tomography/computed tomography (PET/CT) radiomics to determine tumor malignancy and risk stratification in primary prostate cancer (PCa).Wang Z et al analyzed 161 patients with PCa and extracted radiomics features from PCa 18F-PSMA-1007-PET/CT imaging. Prostate-specific antigen (PSA), Gleason score (GS), and PET/CT indexes (SUVmin, SUVmax, and SUVmean) were compared in the patients based on risk stratification.A binary logistic regression and nomogram classifier were created from the radiomics score that integrated clinicopathologic characteristics and specific parameters from the patients.The radiomics signature comprised 30 individual features and was associated with PSA level and GS (P&lt;.001 for both primary and validation cohorts). The individualized prediction nomogram was created using radiomics score, PSA level, and metastasis status. Predictors in the nomogram included radiomics score, PSA level, and metastasis status.The combined clinical-radiomic score nomogram showed a similar benefit to using PET/CT radiomic features alone for GS discrimination. The 18F-PSMA-1007-PET/CT radiomics signature was determined to be useful for facilitating preoperative individualized prediction of GS.

Fluorine-18 PSMA-1007 PET/CT for PCa Risk Stratification

Radioligand therapy prostate-specific membrane antigen

Researchers analyzed 18F-PSMA-1007 PET/CT radiomics for their efficacy in determining tumor malignancy and risk stratification in primary prostate cancer.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe